Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Axsome Therapeutics (AXSM) Rallies After Auvelity Gains FDA Approval

August 19, 2022 2:13 PM EDT

Biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) surged Friday after it announced that the U.S. Food and Drug Administration (FDA) has approved Auvelity for treating major depressive disorder (MDD) in adults.

Axsome shares hit a high of $61.11 following the news. They have since... More

Cowen Reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval

August 19, 2022 10:39 AM EDT

Cowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that AXS-05 (Auvelity) has been approved for the treatment of MDD nearly one year after the therapy's initial PDUFA date.

The analyst... More

Axsome Therapeutics (AXSM) Climbs 40% Following FDA Approval of AUVELITY

August 19, 2022 7:23 AM EDT

Axsome Therapeutics (NASDAQ: AXSM) Climbs 40% Following FDA Approval of AUVELITY

... More